Adicet Bio (ACET) risk factors, FY2024 10-K

Risks Related to Operating History

1. 01We have a limited operating history and face significant challenges and expenses as we build our capabilities
2. 02We have incurred net losses since our inception and anticipate that we will incur substantial net losses in the future

Risks Related to Our Product Candidates

1. 03Our gamma delta T cell candidates represent a novel approach to the treatment of autoimmune diseases and cancer indications that creates significant challenges for us
2. 04establishing sales and marketing capabilities upon obtaining any regulatory approval to gain market acceptance of a novel therapy
3. 05Our product candidates are based on novel technologies, which makes it difficult to predict the likely success of such product candidates and the time and cost of product candidate development and obtaining regulatory approval
4. 06Our product candidates may cause undesirable side effects or have other properties that could halt our clinical development, prevent our regulatory approval, limit our commercial potential or result in significant negative consequences
5. 07of enrolled patients to complete the clinical trial or the commercial viability of any product candidates that obtain regulatory approval

Risks Related to Clinical Trials

1. 08Our clinical trials may fail to demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization
2. 09We may not be able to file IND applications to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed
3. 10We may encounter substantial delays in our clinical trials, or may not be able to conduct our trials on the timelines we expect
4. 11manufacturing challenges, including delays in testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical studies or the inability to do any of the foregoing
5. 12timely manner, if at all, or that submission of an IND application or IND amendment will result in the FDA allowing testing and clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such clinical trials
6. 13Monitoring safety of patients receiving our product candidates is challenging, which could adversely affect our ability to obtain regulatory approval and commercialize
7. 14If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
8. 15the risk that patients enrolled in clinical trials will drop out of the trials before the infusion of our product candidates or trial completion
9. 16Clinical trials are expensive, time-consuming and difficult to design and implement
10. 17A variety of risks associated with conducting research and clinical trials abroad and marketing our product candidates internationally could materially adversely affect our business
11. 18production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad

Risks Related to Marketing Our Product Candidates

1. 19The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small
2. 20If we fail to develop additional product candidates, our commercial opportunity will be limited
3. 21We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively

Risks Related to Manufacturing

1. 22Our cost of goods development is at an early stage. The actual cost to manufacture and process our product candidates could be greater than we expect and could materially and adversely affect the commercial viability of our product candidates
2. 23We may fail to manage the logistics of storing and shipping our product candidates. Storage failures and shipment delays and problems caused by us, our vendors or other factors not in our control, such as weather, could result in loss of usable product or prevent or delay the delivery of product candidates to patients

Risks Related to Our Operations

1. 24We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy
2. 25We will need substantial additional financing to develop our product candidates and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates
3. 26We have grown rapidly and will need to continue to grow the size of our organization, and it may experience difficulties in managing this growth
4. 27improving our operational, financial and management controls, reporting systems and procedures
5. 28We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements

Risks Related to Doing Business in China and Our International Operations

1. 29The pharmaceutical industry in China is highly regulated and such regulations, including the Foreign Investment Law and the “negative list,” are subject to change which may affect development approval and commercialization of our product candidates
2. 30The uncertainties in the PRC legal system regarding the Foreign Investment Law may subject our contractual arrangements to different interpretations or enforcement challenges, or subject us to severe penalties or force us to relinquish our interests in our operations
3. 31restricting or prohibiting use of any of our offering proceeds to finance our business and operations in China, and taking other regulatory or enforcement actions that could be harmful to our business
4. 32We rely on contractual arrangements with the Adicet VIE and its shareholders to undertake the activities of the Adicet VIE that most significantly impact the Adicet VIE’s economic performance, which may not be as effective as direct ownership in providing operational control
5. 33Changes in U.S. and Chinese regulations may impact our business, financial condition, and our operating results
6. 34We may be restricted from transferring our scientific data abroad
7. 35Compliance with China’s Data Security Law, Cyber Security Law, Personal Information Protection Law, regulations and guidelines relating to the multi-level protection scheme on cyber security and any other future laws and regulations may entail significant expenses and could affect our business
8. 36Any failure to comply with Chinese regulations regarding the registration requirements for our employee equity incentive plans may subject us to fines and other legal or administrative sanctions, which could adversely affect our business, financial condition and results of operations

Risks Related to Business Disruptions

1. 37Business disruptions, including armed conflicts, could substantially delay our clinical trials or seriously harm our future revenue and financial condition and increase our costs and expenses
2. 38Global conflicts may increase the likelihood of supply interruptions which could impact our ability to find the materials we need to make our product candidates
3. 39Changes in the political and economic policies or in relations between China and the United States may affect our business, financial condition, and results of operations
4. 40Significant political, trade, regulatory developments, and other circumstances beyond our control, could have a material adverse effect on our financial condition or results of operations

Risks Related to Healthcare Regulation

1. 41Data protection, privacy and similar laws restrict access, use, and disclosure of information, and failure to comply with or adapt to changes in these laws could materially and adversely harm our business
2. 42We believe that increased regulation in additional jurisdictions is likely in the area of data privacy. Any of the foregoing may have a material adverse effect on our ability to provide services to patients and, in turn, our results of operations
3. 43Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data

Risks Related to Our Financial Position

1. 44termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements
2. 45We have in the past failed and may in the future fail to achieve and maintain effective internal control over financial reporting could harm our business and negatively impact the value of our common stock
3. 46A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis

Risks Related to Taxation

1. 47Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited
2. 48The U.S. Congress, the Trump administration, or any new administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business

Risks Related to Third Parties

1. 49If our collaboration with Regeneron is terminated, or if Regeneron materially breaches its obligations thereunder, our business, prospects, operating results, and financial condition would be materially harmed
2. 50Our existing and future collaborations will be important to our business. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected
3. 51collaborations may be terminated by the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates, or potentially lose access to the collaborator’s intellectual property
4. 52We are subject to certain exclusivity obligations under our agreement with Regeneron
5. 53We currently depend and will continue to depend upon independent investigators and collaborators, such as universities, medical institutions, CROs and strategic partners to conduct our preclinical and clinical trials under agreements with us
6. 54We currently rely on third parties to manufacture our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if approved
7. 55Our third-party manufacturers could breach or terminate their agreement(s) with us
8. 56Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all
9. 57If we or our third-party suppliers use hazardous, non-hazardous, biological or other materials in a manner that causes injury or violates applicable law, we may be liable for damages
10. 58Our internal computer systems, or those used by our CROs or other contractors or consultants, may fail or suffer security breaches, incidents, or compromises
11. 59We may not realize the benefits of acquired assets or other strategic transactions
12. 60disruption in our relationships with collaborators or suppliers as a result of such a transaction; and possible write-offs or impairment charges relating to acquired businesses or joint ventures

Risks Related to Regulatory Approval

1. 61The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates
2. 62We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition from biosimilar products
3. 63The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates
4. 64We may seek orphan drug designation for some or all of our product candidates across various indications, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced
5. 65A fast track designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval
6. 66Regenerative Medicine Advanced Therapy (RMAT) designation, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval
7. 67Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions
8. 68injunctions or the imposition of civil or criminal penalties
9. 69Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community, adversely affecting our ability to achieve our commercial and financial projections
10. 70the effectiveness of our sales and marketing efforts
11. 71Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably
12. 72Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance
13. 73neither experimental nor investigational
14. 74The advancement of healthcare reform may negatively impact our ability to sell our product candidates, if approved, profitably
15. 75There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare
16. 76Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability

Risks Related to Our Intellectual Property

1. 77If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market
2. 78whether we will need to initiate litigation or administrative proceedings which may be costly whether we win or lose
3. 79We may require access to additional intellectual property to develop our current or future product candidates. Accordingly, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights
4. 80We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful
5. 81Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
6. 82The lives of our patents may not be sufficient to effectively protect our products and business
7. 83We may be subject to claims challenging the inventorship of our patents and other intellectual property
8. 84Issued patents covering our product candidates could be found unpatentable, invalid or unenforceable if challenged in court or the USPTO

Risks Related to Third Party Intellectual Property

1. 85We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business
2. 86If disputes over intellectual property that we have licensed or license in the future, prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates
3. 87Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information
4. 88Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts

Risks Related to Intellectual Property Laws

1. 89Changes in United States patent law could diminish the value of patents in general, thereby impairing our ability to protect our products
2. 90We may not be able to protect our intellectual property rights throughout the world
3. 91We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties

Risks Related to Ownership Generally

1. 92the other factors described in this “Risk Factors” section
2. 93An active trading market for our common stock may not be sustained. If an active trading market is not sustained, our ability to raise capital in the future may be impaired
3. 94Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval

Risks Related to Market Uncertainties

1. 95Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price
2. 96Our business is affected by macroeconomic conditions, including rising inflation, interest rates and supply chain constraints

Risks Related to our Charter and Bylaws

1. 97Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management
2. 98the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock
3. 99We are a Smaller Reporting Company (SRC) and the reduced disclosure requirements applicable to SRCs may make our common stock less attractive to investors
4. 100We have broad discretion over the use of our cash, cash equivalents and short-term investments and may not use them effectively
5. 101We do not anticipate paying any cash dividends on our capital stock in the foreseeable future. Accordingly, stockholders must rely on capital appreciation, if any, for any return on their investment
6. 102If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline
7. 103If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates
8. 104the inability to commercialize any product candidate
9. 105Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall